The testosterone shortage 2026 is a real and ongoing disruption to the injectable testosterone supply chain in the United States. Testosterone cypionate — the most commonly prescribed injectable TRT medication — has appeared on the FDA drug shortage database repeatedly since 2020, and availability remains patchy at pharmacies across the country in 2026. This article explains what the testosterone shortage 2026 actually means for patients, which products are affected, and the most practical workaround available right now.
Independently researched · Educational information, not medical advice · Affiliate disclosure
What is the testosterone shortage 2026?
The testosterone shortage 2026 refers primarily to supply-chain disruptions affecting testosterone cypionate for injection — the most widely prescribed form of TRT in the U.S. Both brand-name (Depo-Testosterone) and generic versions have experienced intermittent shortages, leaving patients without consistent pharmacy access and forcing some to delay or skip doses.
The shortage is not uniform. Some regions and pharmacy chains have adequate supply while others run dry for weeks at a time. Compounding pharmacies — which mix custom-dose testosterone formulations — have been a partial buffer, but their availability is constrained by DEA scheduling rules for Schedule III controlled substances. And under the current DEA telehealth extension through December 31, 2026, patients can still receive new or renewed prescriptions for testosterone via telehealth without an in-person visit — but only when the underlying medication is available to dispense.
The combination of supply-side shortages, tighter compounding regulations, and the patchwork of telehealth rules makes the testosterone shortage 2026 more complicated to navigate than a simple out-of-stock situation.
Which testosterone products are affected by the shortage?
Not all testosterone products are affected equally. Here is the breakdown:
| Product type | Shortage risk | Notes |
|---|---|---|
| Testosterone cypionate injection (generic) | High | Most commonly shorted; multiple FDA shortage listings since 2020 |
| Depo-Testosterone (brand cypionate) | Moderate–High | Same supply chain as generic; limited buffer stock |
| AndroGel / topical gels | Low–Moderate | Different manufacturing; occasionally short in some markets |
| Testosterone pellets | Low | Smaller market; specialist clinic supply |
| Kyzatrex (oral testosterone undecanoate) | Low | Different manufacturing pathway; FDA-approved oral capsule |
| Compounded testosterone | Moderate | DEA scheduling limits compounder capacity |
The pattern is clear: injectable testosterone cypionate carries the highest shortage risk because it dominates TRT prescriptions and depends on a narrow set of sterile injectable manufacturers. Oral and topical alternatives use different manufacturing pathways and have been more consistently available.
Why is there a testosterone shortage 2026?
The testosterone shortage 2026 traces to several converging pressures:
- Manufacturing concentration. A small number of sterile injectable facilities supply most of the U.S. testosterone cypionate market. Any quality hold, capacity constraint, or supply disruption at one facility ripples across the whole market.
- Post-COVID demand surge. TRT prescriptions grew sharply from 2020 onward as telehealth lowered the barrier to diagnosis. Demand rose faster than manufacturers expanded capacity.
- DEA Schedule III controls. Testosterone is a Schedule III controlled substance. Manufacturing, distribution, and dispensing all require DEA registration and quota compliance, which adds friction and lead time that make it harder to quickly ramp supply.
- FDA label changes and rescheduling discussion. The FDA's removal of the cardiovascular boxed warning from testosterone products (February 2025) and ongoing discussion about de-scheduling testosterone from Schedule III may accelerate demand further in 2026, increasing pressure on an already-strained supply chain. Read our companion piece on the FDA heart-warning removal.
- Compounding restrictions. Compounding pharmacies that once supplied affordable custom testosterone have faced tighter DEA scrutiny, reducing their capacity to fill shortages.
The result: the testosterone shortage 2026 is not a temporary blip. It reflects structural fragility in the injectable TRT supply chain that is unlikely to fully resolve in the near term.
How the testosterone shortage 2026 affects patients
For men currently on TRT via injectables, the testosterone shortage 2026 creates several practical problems:
- Pharmacy gaps. Your regular pharmacy may be out of stock. Calling around to multiple pharmacies or using a specialty compounding pharmacy adds time and friction.
- Delayed prescriptions. Telehealth clinics that source from a single pharmacy partner may pause new patient onboarding during shortage periods.
- Dose interruptions. Going without testosterone for even 2–3 weeks can reverse therapeutic gains (energy, libido, muscle mass, mood) and send levels back to symptomatic lows.
- Cost spikes. When supply tightens, prices can rise — particularly for compounded formulations that are not subject to generic price floors.
For men considering starting TRT, the testosterone shortage 2026 adds uncertainty to an already complex decision: you may get prescribed, pay for labs, and then wait weeks for your medication to ship.
Visit MangoRx and check whether PRIME oral is available in your state →
The needle-free workaround: oral FDA-approved testosterone
The most practical response to the testosterone shortage 2026 is to switch — or start — with a form of testosterone that is not affected by the injectable supply chain: FDA-approved oral testosterone.
Specifically: Kyzatrex (testosterone undecanoate capsules), sold through MangoRx as PRIME, is manufactured via an oral pharmaceutical process entirely separate from the sterile injectable supply chain. It is:
- An FDA-approved prescription capsule (not a supplement or compounded product)
- Taken twice daily with a meal — no injections, no needles
- Not subject to the same supply pressures as testosterone cypionate injection
- Available through telehealth across all 50 states
Unlike injectable testosterone, which requires sterile manufacturing, vials, syringes, and cold chain logistics, oral testosterone undecanoate is produced by standard pharmaceutical tablet/capsule manufacturing. The testosterone shortage 2026 does not apply to it in the same way.
For men currently dealing with injectable shortages — or simply wanting to avoid the risk entirely — PRIME is the most defensible alternative in the mainstream telehealth space.
MangoRx PRIME: the best option during the testosterone shortage 2026
Our full MangoRx review covers the clinic in depth, but the short version relevant to the testosterone shortage 2026 is this: MangoRx is the only mainstream telehealth clinic that offers Kyzatrex/PRIME as a standard offering.
Key facts for shortage-affected patients:
| MangoRx PRIME (oral) | Injectable cypionate (standard) | |
|---|---|---|
| Shortage risk | Low | High |
| Supply chain | Oral pharmaceutical | Sterile injectable |
| FDA status | Approved (Kyzatrex, 2022) | Approved |
| Needles required | ❌ No | ✅ Yes |
| Monthly cost (verified June 2026) | ~$249/mo | $99/mo (MangoRx $99 plan) |
| Telehealth availability | 50 states | 50 states |
The trade-off is cost: PRIME runs approximately $150/mo more than MangoRx's own $99 injectable plan. But if your injectable is consistently unavailable, a $250/mo oral option that actually ships beats a $99/mo injectable that does not.
For men who were never on injectable TRT and are starting fresh, PRIME also removes the learning curve of self-injection — which is particularly relevant now that the testosterone shortage 2026 is adding a second obstacle to starting injectable TRT.
See how oral and injectable TRT compare clinically in our dedicated oral testosterone vs injections guide.
What to do if you are affected by the testosterone shortage 2026
If you are currently on injectable testosterone and running short, here is a practical action plan:
- Call multiple pharmacies. Both retail chains (CVS, Walgreens, Walmart) and independent compounding pharmacies. Availability is local and patchwork.
- Ask your provider about dose bridging. Some protocols allow a temporary dose adjustment or switch to a gel during shortage periods. Never adjust doses without provider guidance.
- Ask about switching to oral TRT. If your prescriber is open to it, Kyzatrex (PRIME) is an FDA-approved alternative that sidesteps the cypionate supply chain. MangoRx providers are specifically experienced with this transition.
- Start fresh with oral if you haven't started TRT yet. If you have been delaying TRT because of injection anxiety, the testosterone shortage 2026 is a strong reason to look at PRIME from the beginning rather than going injectable and risking supply gaps.
- Check the FDA shortage database. The FDA drug shortage list is the most authoritative source on current inventory status by product and manufacturer.
Get started with MangoRx PRIME — avoid the shortage entirely →
Will the testosterone shortage 2026 end?
The testosterone shortage 2026 is unlikely to resolve completely in the short term. The FDA's removal of the testosterone cardiovascular warning in February 2025 and ongoing Schedule III de-scheduling discussions will continue to push demand higher. Manufacturing capacity expansions take 2–4 years to reach market, and the DEA quota system for Schedule III substances does not allow overnight scaling.
The more durable solution for individual patients is to reduce dependence on injectable supply chains by choosing a delivery method — oral testosterone, gel, or cream — that draws on a different manufacturing base. For men who need or strongly prefer injectables, building a relationship with a compounding pharmacy and maintaining a buffer supply (within DEA legal limits) is the most practical risk-management step.
The testosterone shortage 2026 is a structural problem. The workaround is a product choice.
Frequently asked questions about the testosterone shortage 2026
Is testosterone cypionate currently on the FDA shortage list? Testosterone cypionate has appeared on and off the FDA drug shortage list multiple times since 2020. Check the FDA drug shortage database for the current status — it is updated regularly and lists which manufacturers are affected.
Can I still get injectable TRT during a shortage? Yes, often — but it requires checking multiple pharmacies. Supply is uneven by region and pharmacy. Telehealth clinics that partner with large pharmacy networks typically have better access than local independent pharmacies.
Is oral testosterone a medically equivalent substitute for injections? Kyzatrex (oral testosterone undecanoate) raises serum testosterone into the normal eugonadal range and carries FDA approval for men with hypogonadism. It is medically valid. The pharmacokinetics differ from injectables — dosing timing, absorption, and lab interpretation all require prescriber guidance. It is not a "supplement workaround." See our oral vs injectable TRT guide for the full clinical comparison.
Does the testosterone shortage 2026 affect compounded testosterone? Yes. Compounding pharmacies are constrained by DEA Schedule III quotas, which limit how much testosterone they can produce and dispense. If retail manufacturers are short, compounders cannot easily absorb the overflow at scale.
How does the DEA telehealth extension affect the shortage? The DEA extended telehealth prescribing for Schedule III controlled substances (including testosterone) through December 31, 2026. This means you can still get a new or renewed TRT prescription via telehealth without an in-person visit — but only if the medication is available to be dispensed. The extension affects prescription access, not physical drug supply.
Which TRT clinics are best positioned during the shortage? Clinics that offer oral testosterone (Kyzatrex/PRIME) as a standard option are best positioned because they can route new patients to a supply chain unaffected by the injectable shortage. MangoRx is the only mainstream telehealth platform we track that offers this. See our full clinic rankings and MangoRx review for context.
The testosterone shortage 2026: the bottom line
The testosterone shortage 2026 is real, ongoing, and structurally rooted in concentrated sterile injectable manufacturing. For patients and new starters, the most defensible response is to choose a testosterone form that does not depend on that supply chain. FDA-approved oral testosterone (Kyzatrex/PRIME via MangoRx) is the clearest available path.
For a full cost comparison across clinics — including who has oral options and who does not — use our cheapest TRT clinics guide and our compare tool.
Visit MangoRx — check PRIME oral availability and pricing →
Related reading
- MangoRx Review 2026: $99 Injectable + PRIME Oral TRT
- Oral Testosterone vs Injections: Full Comparison
- FDA Drops Testosterone Heart Warning: What It Means (2026)
- Best Online TRT Clinics 2026 — Full Rankings
- Cheapest Online TRT: 2026 Price Ranking
Medical disclaimer: this article is for informational purposes only and is not medical advice. Testosterone therapy is a prescription treatment — consult a licensed clinician before making any changes to your protocol. Affiliate disclosure: TRT Picks may earn a commission if you sign up through links on this page, at no extra cost to you. Commission never influences our scores or editorial positions. See our affiliate disclosure. Last updated June 2026.
